Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2011, to April 30, 2012. The report details the status of various share option schemes and block listing returns as of May 9, 2012.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation plan statistics.
Material Changes in Share Option Schemes
Significant activity occurred in two primary schemes during the reporting period:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: The unallotted balance increased by 15,000,000 shares. After issuing 5,353,854 shares, the remaining balance was 14,090,687.
- GlaxoSmithKline Share Option Plan - ADS: The unallotted balance increased by 15,000,000 shares. After issuing 12,710,138 shares, the remaining balance was 5,537,568.
- GlaxoSmithKline Savings Related Share Option Scheme: No increase in the block was applied for. 3,787,708 shares were issued, reducing the balance to 4,005,708.
- Other Schemes: The Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, and SmithKline Beecham 1989 plans reported no increases and no issuances during this period.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a statutory return regarding share option block listings.
Key Facts for Investor Verification
- Verify the total number of shares issued under the Ordinary Shares and ADS plans (18,063,992 combined) against the company's treasury stock or authorized share count.
- Confirm the 15,000,000 share increase applied to both the Ordinary Shares and ADS plans was approved by shareholders or the board as required.
- Review the remaining unallotted balances to assess future dilution potential from these specific schemes.